298 related articles for article (PubMed ID: 33815613)
1. PI3K/AKT/mTOR signalling pathway involvement in renal cell carcinoma pathogenesis (Review).
Miricescu D; Balan DG; Tulin A; Stiru O; Vacaroiu IA; Mihai DA; Popa CC; Papacocea RI; Enyedi M; Sorin NA; Vatachki G; Georgescu DE; Nica AE; Stefani C
Exp Ther Med; 2021 May; 21(5):540. PubMed ID: 33815613
[TBL] [Abstract][Full Text] [Related]
2. Xihuang pills induce apoptosis in hepatocellular carcinoma by suppressing phosphoinositide 3-kinase/protein kinase-B/mechanistic target of rapamycin pathway.
Teng YJ; Deng Z; Ouyang ZG; Zhou Q; Mei S; Fan XX; Wu YR; Long HP; Fang LY; Yin DL; Zhang BY; Guo YM; Zhu WH; Huang Z; Zheng P; Ning DM; Tian XF
World J Gastrointest Oncol; 2022 Apr; 14(4):872-886. PubMed ID: 35582102
[TBL] [Abstract][Full Text] [Related]
3. mTOR in renal cell cancer: modulator of tumor biology and therapeutic target.
Wysocki PJ
Expert Rev Mol Diagn; 2009 Apr; 9(3):231-41. PubMed ID: 19379082
[TBL] [Abstract][Full Text] [Related]
4. Mammalian Target of Rapamycin Inhibitors Resistance Mechanisms in Clear Cell Renal Cell Carcinoma.
Kornakiewicz A; Solarek W; Bielecka ZF; Lian F; Szczylik C; Czarnecka AM
Curr Signal Transduct Ther; 2014 Dec; 8(3):210-218. PubMed ID: 25152703
[TBL] [Abstract][Full Text] [Related]
5. Targeting mTOR pathways in human malignancies.
Fasolo A; Sessa C
Curr Pharm Des; 2012; 18(19):2766-77. PubMed ID: 22475451
[TBL] [Abstract][Full Text] [Related]
6. Jagged-1 is induced by mTOR inhibitors in renal cancer cells through an Akt/ALK5/Smad4-dependent mechanism.
Danielpour D; Corum S; Leahy P; Bangalore A
Curr Res Pharmacol Drug Discov; 2022; 3():100117. PubMed ID: 35992379
[TBL] [Abstract][Full Text] [Related]
7. Characterization and targeting of phosphatidylinositol-3 kinase (PI3K) and mammalian target of rapamycin (mTOR) in renal cell cancer.
Elfiky AA; Aziz SA; Conrad PJ; Siddiqui S; Hackl W; Maira M; Robert CL; Kluger HM
J Transl Med; 2011 Aug; 9():133. PubMed ID: 21834980
[TBL] [Abstract][Full Text] [Related]
8. Targeting the phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway: an emerging treatment strategy for squamous cell lung carcinoma.
Beck JT; Ismail A; Tolomeo C
Cancer Treat Rev; 2014 Sep; 40(8):980-9. PubMed ID: 25037117
[TBL] [Abstract][Full Text] [Related]
9. FoxO transcription factors promote AKT Ser473 phosphorylation and renal tumor growth in response to pharmacologic inhibition of the PI3K-AKT pathway.
Lin A; Piao HL; Zhuang L; Sarbassov dos D; Ma L; Gan B
Cancer Res; 2014 Mar; 74(6):1682-93. PubMed ID: 24448243
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic Potential of Autophagy in Glioblastoma Treatment With Phosphoinositide 3-Kinase/Protein Kinase B/Mammalian Target of Rapamycin Signaling Pathway Inhibitors.
Xia Q; Xu M; Zhang P; Liu L; Meng X; Dong L
Front Oncol; 2020; 10():572904. PubMed ID: 33123479
[TBL] [Abstract][Full Text] [Related]
11. A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma.
Korkolopoulou P; Levidou G; Trigka EA; Prekete N; Karlou M; Thymara I; Sakellariou S; Fragkou P; Isaiadis D; Pavlopoulos P; Patsouris E; Saetta AA
BJU Int; 2012 Dec; 110(11 Pt C):E1237-48. PubMed ID: 23107319
[TBL] [Abstract][Full Text] [Related]
12. PI3K-Akt-mTOR inhibition by GNE-477 inhibits renal cell carcinoma cell growth
Ye X; Ruan JW; Huang H; Huang WP; Zhang Y; Zhang F
Aging (Albany NY); 2020 May; 12(10):9489-9499. PubMed ID: 32421688
[TBL] [Abstract][Full Text] [Related]
13. CEP55 promotes epithelial-mesenchymal transition in renal cell carcinoma through PI3K/AKT/mTOR pathway.
Chen H; Zhu D; Zheng Z; Cai Y; Chen Z; Xie W
Clin Transl Oncol; 2019 Jul; 21(7):939-949. PubMed ID: 30607788
[TBL] [Abstract][Full Text] [Related]
14. NVP-BEZ235 Inhibits Renal Cell Carcinoma by Targeting TAK1 and PI3K/Akt/mTOR Pathways.
Li B; Zhang X; Ren Q; Gao L; Tian J
Front Pharmacol; 2021; 12():781623. PubMed ID: 35082669
[TBL] [Abstract][Full Text] [Related]
15. Recent Updates on the Involvement of PI3K/AKT/mTOR Molecular Cascade in the Pathogenesis of Hyperproliferative Skin Disorders.
Mercurio L; Albanesi C; Madonna S
Front Med (Lausanne); 2021; 8():665647. PubMed ID: 33996865
[TBL] [Abstract][Full Text] [Related]
16. Morphoproteomics and biomedical analytics confirm the mTORC2/Akt pathway as a resistance signature and activated ERK and STAT3 as concomitant prosurvival/antiapoptotic pathways in metastatic renal cell carcinoma (RCC) progressing on rapalogs: pathogenesis and therapeutic options.
Brown RE; Buryanek J; Tammisetti VS; McGuire MF; Csencsits-Smith K
Oncotarget; 2016 Jul; 7(27):41612-41621. PubMed ID: 27223432
[TBL] [Abstract][Full Text] [Related]
17. Benchmarking effects of mTOR, PI3K, and dual PI3K/mTOR inhibitors in hepatocellular and renal cell carcinoma models developing resistance to sunitinib and sorafenib.
Serova M; de Gramont A; Tijeras-Raballand A; Dos Santos C; Riveiro ME; Slimane K; Faivre S; Raymond E
Cancer Chemother Pharmacol; 2013 May; 71(5):1297-307. PubMed ID: 23479136
[TBL] [Abstract][Full Text] [Related]
18. Mammalian target of rapamycin: biological function and target for novel anticancer agents.
Borders EB; Bivona C; Medina PJ
Am J Health Syst Pharm; 2010 Dec; 67(24):2095-106. PubMed ID: 21116000
[TBL] [Abstract][Full Text] [Related]
19. Identification of novel mycocompounds as inhibitors of PI3K/AKT/mTOR pathway against RCC.
Yadav RP; Chatterjee S; Chatterjee A; Pal DK; Ghosh S; Acharya K; Das M
J Recept Signal Transduct Res; 2022 Dec; 42(6):599-607. PubMed ID: 36125981
[TBL] [Abstract][Full Text] [Related]
20. Targeting the PI3K/AKT/mTOR pathway in epithelial ovarian cancer, therapeutic treatment options for platinum-resistant ovarian cancer.
Rinne N; Christie EL; Ardasheva A; Kwok CH; Demchenko N; Low C; Tralau-Stewart C; Fotopoulou C; Cunnea P
Cancer Drug Resist; 2021; 4(3):573-595. PubMed ID: 35582310
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
